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Abstract
To date, there is no clear agreement regarding which is the best method to detect a connective tissue disease (CTD) during the initial
diagnosis of interstitial lung diseases (ILD). The aim of our study was to explore the impact of a systematic diagnostic strategy to
detect CTD-associated ILD (CTD-ILD) in clinical practice, and to clarify the significance of interstitial pneumonia with autoimmune
features (IPAF) diagnosis in ILD patients.
Consecutive patients evaluated in an ILD Diagnostic Program were divided in 3 groups: IPAF, CTD-ILD, and other ILD forms.
Clinical characteristics, exhaustive serologic testing, high resolution computed tomography (HRCT) images, lung biopsy specimens,
and follow-up were prospectively collected and analyzed.
Among 139 patients with ILD, CTD was present in 21 (15.1%), 24 (17.3%) fulfilled IPAF criteria, and 94 (67.6%) were classified as
other ILD forms. Specific systemic autoimmune symptoms such as Raynaud phenomenon (19%), inflammatory arthropathy (66.7%),
and skin manifestations (38.1%) were more frequent in CTD-ILD patients than in the other groups (all P< .001). Among
autoantibodies, antinuclear antibody was the most frequently found in IPAF (42%), and CTD-ILD (40%) (P= .04). Nonspecific
interstitial pneumonia, detected by HRCT scan, was the most frequently seen pattern in patients with IPAF (63.5%), or CTD-ILD
(57.1%) (P< .001). In multivariate analysis, a suggestive radiological pattern by HRCT scan (odds ratio [OR] 15.1, 95% confidence
interval [CI] 4.7–48.3, P< .001) was the strongest independent predictor of CTD-ILD or IPAF, followed by the presence of clinical
features (OR 14.6, 95% CI 4.3–49.5, P< .001), and serological features (OR 12.4, 95% CI 3.5–44.0, P< .001).
This systematic diagnostic strategy was useful in discriminating an underlying CTD in patients with ILD. The defined criteria for IPAF
are fulfilled by a considerable proportion of patients referred for ILD.
Abbreviations: ANA = antinuclear antibody, ANCA = antineutrophil cytoplasmic antibodies, ASSD = antisynthetase syndrome,
CCP = anti-cyclic citrullinated peptide, CTD = connective tissue disease, FVC = forced vital capacity, HRCT = high resolution
computed tomography, IIP = idiopathic interstitial pneumonia, ILD = interstitial lung disease, IPAF = interstitial pneumonia with
autoimmune features, IPF = idiopathic pulmonary fibrosis, LIP = lymphoid interstitial pneumonia, NSIP = nonspecific interstitial
pneumonia, OP= organizing pneumonia, PPV= positive predictive value, RF= rheumatoid factor, SLB= surgical lung biopsy, UCTD
= undifferentiated connective tissue disease, UIP = usual interstitial pneumonia.
Keywords: autoimmune disease, idiopathic interstitial pneumonias, interstitial pneumonia, nonspecific interstitial pneumonia,
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Connective tissue diseases (CTD) encompass a heterogeneous
group of autoimmune disorders including systemic lupus eryth-
ematosus, systemic sclerosis, idiopathic inflammatorymyopathies,
Sjögren syndrome, and rheumatoid arthritis. Interstitial lung
disease (ILD) is awell-recognizedand severemanifestationofmany
CTD that impacts on the prognosis and management in many of
these patients.[1–4] However, there is no clear agreement regarding
which is the best method to detect a CTD during the initial
diagnosis of ILDs. Besides, despite recent technological advances,
thepreciseprevalence rates of ILDamong thevariousCTDsare not
known and are influenced by the methods of detection.[5–9]
Although serological testing is recommended by international
guidelines, [10,11] it is not clearwhich antibodiesmust be included in
the initial evaluation of an ILD patient in order to detect an
underlying CTD accurately. A rheumatoid factor (RF), anti-cyclic
citrullinated peptide (CCP), and antinuclear antibody (ANA) titer
andpattern seemed tobegenerally accepteduntil now.[1]However,
it has not been establishedwhether adding other autoantibodies to
the initial serologic tests could improve the diagnosis of CTD in
patients with ILD. This could be relevant as a large number of
patients who would have previously been categorized as having
idiopathic interstitial pneumonia (IIP) by the recently revised IIP
criteria are now likely to have an underlying CTD. Therefore,
identifying occult or incomplete forms of CTD in patients with
presumed IIP can be challenging.[1,12]
Moreover, it is not uncommon for ILDs to be the initial
manifestation of an underlying CTD, even preceding extrapulmo-
nary symptoms by several years.[13] This “lung-dominant”
presentation could complicate the diagnosis, as many patients
present a constellation of clinical, serologic, or morphological
findings that belong to the spectrum of CTDs, but do not fulfill the
classification criteria for CTD. [14–20] Such patients are now
considered to have a syndrome recently named as “interstitial
pneumonia with autoimmune features” (IPAF).[21] Although IPAF
has been recently definedby a recent InternationalConsensusTask
Force made up of experts from the European Respiratory Society
(ERS) and the American Thoracic Society (ATS), the proposed
criteria for this entity has not been tested or validated so far.
Thus, the present study was conducted to explore the impact of
a systematic diagnostic strategy to detect CTD-ILD during an
ILD diagnostic program that included an extensive assessment of
clinical signs, symptoms, and autoantibodies. Furthermore, we
attempted to clarify the incidence and the clinical characteristics
of IPAF at the initial assessment of ILD diagnosis.2. Methods
2.1. Study design and population
This is a clinical descriptive study of a total of 146 patients
evaluated at an ILD Diagnostic Program of a tertiary referral
center. Data from all patients prospectively and consecutively
included in the ILD Diagnostic Program from January 2013 to
January 2014 was assessed. As part of their initial assessment, a
complete and systematic anamnesis and physical examination,
including a broad range of autoimmune disease symptoms and
signs, and awide serologic testing for CTD, was obtained from all
subjects at the time of initial diagnosis and periodically during 1-
year follow-up. The study was approved by the Ethics Committee
of the Hospital Clinic of Barcelona, and informed consent from
all participants was obtained.2
2.2. Autoimmune clinical features
All patients were assessed for extrathoracic specific features
suggestive of an underlying CTD, including Raynaud phenome-
non, arthralgia/arthritis, morning stiffness, skin manifestations
(cutaneous sclerosis, distal digital fissuring or tip ulceration,
telangiectasia, Gottron sign, heliotrope rash), oral ulceration, and
digital edema. Other nonspecific features, but commonly related
to CTD, such as nonandrogenic alopecia, dry eyes or dry mouth,
photosensitivity, unintentional weight loss, dysphagia, recurrent
unexplained fever, gastroesophageal reflux, or proximal muscle
weakness, were also explored.2.3. Autoantibody tests
All patients underwent serologic tests for autoantibodies at the
time of diagnosis. ANA and antineutrophil cytoplasmic anti-
bodies (ANCA) were tested using indirect immunofluorescence
(IIF). Anti-Ro (SS-A), anti-La (SS-B), anti-ribonucleoprotein,
anti-Smith, anti-double-stranded DNA (dsDNA), anti-cyclic
CCP, anti-Scl-70, anti-centromere, anti-Ro52, and anti-Jo1
antibodies, were tested using enzyme-linked immunosorbent
assay (ELISA). RF was measured using latex agglutination.
Specific ANCA (MPO and PR3) was also determined by ELISA.
Moreover, anti-dsDNA (Crithidia luciliae) antibodies were also
tested by IIF, anti-Mi2, anti-Ku, anti-PM-Scl (75 and 100
subunits), anti-PL7, anti-PL12, anti-OJ, anti-EJ, and anti-SRP
antibodies were measured using Dot-Blot method. The serologic
tests were considered positive if the circulating autoantibody
levels were above the manufacturer reference value, with the
exception of ANA and RF. ANA was considered positive if the
titer were 1:320 or higher with diffuse, speckled, homogeneous
patterns, or any titer with nucleolar or centromere pattern. RF
was considered positive if the titer was≥2x upper limit of normal.2.4. High-resolution CT scan evaluation
A high-resolution CT (HRCT) scan was performed at the time of
initial evaluation in all patients. HRCT examination of the lungs
was performed on 1.0-or-1.5-mm-thick sections to evaluate
radiographic abnormalities. Chest radiologists experienced in the
interpretation of diffuse lung disease reviewed all HRCT scan
images. HRCT diagnosis was made by the definitions accepted by
international guidelines.[10,11,22] If there was disagreement in the
assessment of the findings, consensus was reached via discussion
between the investigators.2.5. Histopathology
Lung biopsy was performed in selected patients after a
multidisciplinary discussion. All lung biopsy specimens were
evaluated by an expert pulmonary pathologist with experience
and advanced training in the evaluation of ILDs, and were
classified using the histopathologic patterns described in the
international guidelines.[10,11,22] All specimens were evaluated
prospectively as an integral part of clinical care.2.6. Diagnostic criteria and clinical follow-up
Rheumatic and autoimmune diseases were defined according to
the updated classification criteria.[23–28] Patients with complete or
incomplete forms of antisynthetase syndrome (ASSD), were
assessed using the American and European NEtwork of
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definition.[29]
Proposed classification criteria for IPAF were taken into
consideration after the “ERS/ATS research statement of IPAF”
was published.[21] Patients were considered to have a diagnosis of
IPAF if they met all of the a priori requirements, and had at least 1
feature from at least 2 of the proposed clinical, serologic or
morphologic domain. The proposed clinical and serological
features for the diagnosis criteria of IPAF were considered to be
specific features suggestive of CTD.[21] The radiologic patterns
considered to be suggestive of CTD were nonspecific interstitial
pneumonia (NSIP), organizing pneumonia (OP), NSIP with OP,
and lymphoid interstitial pneumonia (LIP), as defined by ERS/ATS
research statement of IPAF.[21] Diagnosis of other forms of ILD
was based on history, clinical assessment, HRCT scan, and
histologic examination when performed, in accordance with the
ATS/ERS Consensus Classification.[10,11,22] Diagnosis was con-
firmed by consensus of a multidisciplinary panel of ILD experts.
Improvement/deterioration of ILD was defined as a change of
≥10% in the forced vital capacity (FVC) and/or ≥15% in the
diffusing capacity of carbon monoxide.[10,30] Survival status was
evaluated at 1-year follow-up.2.7. Multidisciplinary diagnosis
Diagnosis of ILDs was done through multidisciplinary discussion
based on clinical characteristics along with HRCT and lung
biopsy patterns if appropriate. Multidisciplinary discussions
were conducted between pulmonologists, radiologists, and
pathologists experienced in the diagnosis of ILD. Bronchoscop-
ists, thoracic surgeons, and autoimmune specialists were also
included.2.8. Statistical analysis
Analyses were performed using the Predictive Analytics Software
Statistics statistical software (version 18.0, SPSS Japan Inc,
Tokyo, Japan). Continuous variables were presented as mean ±
standard deviation if normally distributed, while non-normally
distributed continuous variables were summarized as median and
interquartile range. Kolmogorov–Smirnov testing identified
states of non-normality. The Chi-squared test (or Fisher exact
test) was used to compare categorical data. Continuous variables
were compared using the analysis of variance with post hoc
Bonferroni correction. The survival probability of etiological
groups was estimated using the Kaplan–Meyer method and
compared with Log-rank test. Survival was evaluated from the
date of inclusion, which corresponds to the date of the initial
diagnosis, until the end of the follow-up period.
Multivariate logistic regression was performed to assess the
predictive value of different variables for a CTD-ILD or IPAF
diagnosis. Univariate analysis was performed first, and all the
variables that exhibited a P< .05 or those clinically relevant were
entered in the multivariate model. Model fit was assessed using
receiver operating characteristic curves analyses. Cox and Snell
R2 and NagelkerkeR2 were used to identify the amount of
variation in the dependent variable explained by the model. Also,
we set out to construct a decision tree analysis, a nonparametric
statistical method used to assess the incidence of CTD-ILD or
IPAF, and to screen for the most important relevant predictive
factors. The decision tree model was developed using those
significant or clinically relevant variables previously reported. A3
P-value< .05 was established as the level of statistical significance
for all tests.3. Results
3.1. Multidisciplinary evaluation in the ILD program and
prevalence of CTD or IPAF
Among 146 consecutive patients evaluated in the ILD Program
(Fig. 1), 7 patients were excluded because another lung disease,
different from ILD, was finally diagnosed. Among the 139
patients assessed, 10 (7.2%) initially fulfilled the criteria of a
known CTD.[23–28] Autoimmune disease specialists evaluated 72
(51.8%) patients because they presented any symptoms or any
antibody suggestive of CTD.Of these, 11 (7.9%) patients fulfilled
the CTD criteria, and 32 (23%) fulfilled IPAF criteria, and were
presented again at the multidisciplinary committee. A total of 24
(17.3%) patients were finally classified as IPAF. From the group
of IPAF patients, 16 fulfilled at least 1 serologic and 1
morphologic feature, 3 presented at least 1 serologic and 1
clinical feature, 2 presented at least 1 clinical and 1 morphologic
feature, and 3 patients presented at least 1 feature from each
domain. A total of 94 (67.6%) patients were finally diagnosed
with other forms of ILD. Among the group of patients presenting
other forms of ILD, 15 (10.8%) were diagnosed with idiopathic
pulmonary fibrosis (IPF), 6 (4.3%) with possible IPF, 13 (9.4%)
with idiopathic NSIP, 13 (9.4%) with hypersensitivity pneumo-
nitis, 9 (6.5%) with sarcoidosis, 8 (5.8%) with OP, 3 (2.2%) with
Langerhans cell’s granulomatosis, and 27 (19.4%) with other
forms of ILD.
3.2. Clinical characteristics, pulmonary function tests, and
bronchoalveolar lavage
Baseline characteristics are summarised in Table 1. Patients were
distributed in 3 groups according to the etiology of ILD: IPAF
(n=24), CTD-ILD (n=21), and other ILD forms (n=94). CTD-
ILD patients were divided as follows: Sjögren syndrome (n=6),
systemic sclerosis (n=5), rheumatoid arthritis (n=6), dermato-
myositis (n=3, including 2 patients with ASSD), and systemic
lupus erythematosus (n=1). Patients with IPAF and CTD-ILD
were more likely to be females than those with other forms of ILD
(75%and 76% versus 40%, respectively; P< .001). Interestingly,
there were significant differences in the results of pulmonary
function tests, with a higher FVC (FVC%predicted) (P= .001), a
higher forced expiratory volume in the first second (FEV1%
predicted) (P= .008), and a higher total lung capacity (%
predicted) (P= .02) in patients with IPAF.3.3. Systemic autoimmune symptoms and laboratory
findings
Results are shown in Tables 2 and 3. Specific systemic
autoimmune symptoms such as Raynaud phenomenon (19%),
inflammatory arthropathy (66.7%), and skin manifestations
(38.1%) were more frequent in CTD-ILD patients than in the
other groups (all P< .001). The most frequent non-specific
systemic autoimmune symptoms in CTD-ILD patients were
proximal muscle weakness (19%), and recurrent unexplained
fever (14.3%). By contrast, IPAF patients presented more
frequently with sicca symptoms (dry eyes, 37.5%; dry mouth,
50%) and gastroesophageal reflux (71%).
Figure 1. Flow diagram for diagnostic protocol used for the screening of connective tissue disease related interstitial lung disease. CTD=connective tissue
disease, CTD-ILD=connective tissue disease-associated interstitial lung disease; HP=hypersensitivity pneumonia, ILD= interstitial lung disease, IPAF= interstitial
pneumonia with autoimmune features, MDD=multidisciplinary committee.
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feature was higher in IPAF and CTD-ILD than that observed in
other ILD forms (100% vs 15%, P= .001). Moreover, 52% of
patients with CTD-ILD presented at least 2 clinical autoimmune
features, a higher rate than that observed in patients with IPAF
and other forms of ILD (44% and 15%, respectively, P= .001).
All patients with IPAF and CTD-ILD had at least 1
autoimmune antibody. Among autoantibodies, a positive ANA
was the most frequently found in IPAF (42%), and CTD-ILD
(40%). The incidence of positive ANA was significantly higher in
IPAF and CTD-ILD patients than in other ILD forms (P= .04). In
addition, the group of IPAF and CTD-ILD patients were more
likely to have a relative frequency of higher ANA titres (1:320)
(P< .05). The positive rates of RF (36.8%, P= .001), anti-Ro
(25%, P= .001), anti-Jo1 antibody (12.5%, P= .01), anti-Scl70
(18.8%, P< .001), and anti-Ro52 (31.2%, P< .001) were
significantly higher in CTD-ILD patients than in the other
groups, as expected. Anti-PL7 antibody was positive in 12.5% of
IPAF patients, with no ex novo manifestations of ASSD during
the follow up.3.4. Morphologic findings
There were significant differences between the 3 groups regarding
HRCT scan patterns (P= .001) (Table 4). A HRCT scan pattern4
suggestive of or consistent with NSIP was the most frequently
seen in patients with IPAF (63.5%), or CTD-ILD (57.1%).
Nevertheless, it is noteworthy that other patterns different from
NSIP were present in patients with IPAF and CTD-ILD: usual
interstitial pneumonia (UIP) (4.2% and 9.5%, respectively); and
other patterns (25% and 14.3%, respectively). Significant
differences were also seen between patients that required a
pulmonary biopsy with a histopathologic pattern of UIP. This
pattern was present in 2 (8.3%) IPAF patients, and 3 (14.3%)
CTD-ILD patients (P= .02).3.5. Predictive factors of CTD-ILD or IPAF diagnosis and
decision tree analysis
Results of the multivariate analyses independent predictors of
CTD-ILD or IPAF diagnosis showed that the strongest predictor
was a suggestive radiological pattern by HRCT scan (odds ratio
[OR] 3.32, 95% confidence interval [CI] 1.24–9.00; P< .001),
followed by the presence of specific clinical features (OR 3.32,
95% CI 1.24–9.00; P< .001), and the presence of specific
serological features (OR 12.37, 95% CI 3.46–44; P< .001)
(Fig. 2). The regressionmodel also had a very highNagelkerke R2
of 0.66, and correctly classified 87.1% of patients. The area
under the curve was 0.65 (95% CI 0.55–0.76; P= .004). This
model had a high sensitivity (81.4%, 95% CI 67.4–90.3), high
Table 1
Baseline characteristics according to etiological groups.
IPAF
∗
(n=24) CTD-ILD (n=21) Other ILD forms (n=94) P
Demographics
Female 18 (75%) 16 (76%) 38 (40%)†,x <.001
Smoking .07
Never 15 (63%) 12 (57%) 42 (45%)
Current 4 (17%) 0 (0%) 7 (7%)
Former 5 (21%) 9 (43%) 45 (48%)†
Age, years 71 (61–80) 66 (57–73) 67 (57–75) .20
Clinical characteristics
Cough 14 (58%) 13 (62%) 46 (50%) .49
Dyspnea (mMRC, 1–2/3–4) 11 (46%) / 6 (25%) 16 (76%) / 3 (14%) 57 (61%) / 19 (20%) .33
Crackles 14 (58%) 19 (91%)‡ 59 (63%)x .09
Clubbing 7 (32%) 4 (19%) 25 (27%) .63
Pulmonary function testing
FEV1 (% predicted) 84.9 (±19.6) 69.2 (±17.1)
‡ 66.6 (±15.6)† <.001
FVC (% predicted) 78.6 (±21.1) 66.8 (±17.1) 66.2 (±16.0)† .01
FEV1/FVC (%) 79.5 (±7.9) 79.9 (±5.1) 83.9 (±7.5) .12
TLC (% predicted) 82.6 (±16.5) 72.4 (±17.8) 70.7 (±15.6)† .02
DLCO (% predicted) 56.2 (±20.2) 49 (±20.6) 47.6 (±16.4) .31
BALF findings
M (%) 73 (38–93) 79 (48–92) 80 (69–89) .88
N (%) 6 (0–48) 5 (1–12) 5 (2–15) .92
L (%) 4 (2–28) 5 (3–20) 7 (3–14) .99
E (%) 0 (0–1) 0 (0–4) 0 (0–3) .55
BALF=bronchoalveolar lavage fluid, CTD-ILD= connective tissue disease-associated interstitial lung disease, DLCO=diffusion capacity for carbon monoxide, E= eosinophils, FEV1= forced expiratory volume in
the first second, FVC= forced vital capacity, ILD= interstitial lung disease, IPAF= interstitial pneumonia with autoinmune features, L= lymphocites, M=macrophages, mMRC=modified Medical Research
Council, N=neutrophils, TLC= total lung capacity.
Prebronchodilator pulmonary function measurements presented.
∗
IPAF as defined by the European Respiratory Society/American Thoracic Society research statement’s criteria.[21]
† P< .05 for comparison between IPAF and other ILD forms groups.
‡ P< .05 for comparison between IPAF and CTD-ILD groups.
x P< .05 for comparison between CTD-ILD and other ILD forms groups.
Table 2










Raynaud phenomenon 1 (4.2%) 4 (19%) 1 (1.1%)x <.001
Inflammatory arthropathy 9 (37.5%) 14 (66.7%) 9 (9.9%)†,x <.001
Morning stiffness 0 (0%) 0 (0%) 2 (2.1%) .62
Digital edema 0 (0%) 0 (0%) 0 (0%)
Proximal muscle weakness 0 (0%) 4 (19%)‡ 0 (0%)x <.001
Dry eyes 9 (37.5%) 4 (20%) 9 (9.8%)†,x .004
Dry mouth 12 (50%) 7 (35%) 10 (10.8%)†,x <.001
Dysphagia 3 (12.5%) 3 (14.3%) 9 (9.7%) .80
Photosensitivity 0 (0%) 0 (0%) 0 (0%)
Skin manifestationsjj 2 (8.3%) 8 (38.1%)‡ 7 (7.5%)x <.001
Oral ulceration 0 (0%) 0 (0%) 0 (0%)
Nonandrogenic alopecia 0 (0%) 0 (0%) 0 (0%)
Recurrent unexplained fever 0 (0%) 3 (14.3%) 3 (3.2%)x .04
Unintentional weight loss 1 (4.2%) 1 (4.8%) 2 (2.1%) .74
Gastroesophageal reflux 17 (70.8%) 8 (38.1%)‡ 42 (45.2%) .05
CTD-ILD= connective tissue disease-associated interstitial lung disease, ILD= interstitial lung
disease, IPAF= interstitial pneumonia with autoimmune features.
∗
IPAF as defined by the European Respiratory Society/American Thoracic Society research
statement’s criteria[21].
† P< .05 for comparison between IPAF and other ILD forms groups.
‡ P< .05 for comparison between IPAF and CTD-ILD groups.
x P< .05 for comparison between CTD-ILD and other ILD forms groups.
jj Skin manifestations include cutaneous sclerosis, distal digital fissuring or tip ulceration,
telangiectasia, Gottron sign, or heliotrope rash.
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specificity (89.6%, 95%CI 81.9–94.2), with a positive predictive
value (PPV) of 77.8% (95% CI 63.7–87.5), and a negative
predictive value of 91.5% (95% CI 84.1–95.6), confirming the
usefulness of excluding individuals with ILD and features
suggestive of a CTD.
The decision tree analysis showed that the most important
predictive factor for CTD-ILD or IPAF diagnosis was a suggestive
radiological pattern by HRCT scan, followed by the presence of
specific clinical features and specific serologic features (Fig. 3).
However, to be considered as having a CTD-ILD or IPAF, a
patient with any other radiological pattern than NSIP, OP, NSIP
with OP, or LIP, would need to have at least 1 clinical feature and
1 serologic feature.
3.6. Clinical follow-up
As expected, the etiological groups differed in terms of the
treatments received (Table 5). The CTD-ILD group had a
significantly higher percentage of patients treated with myco-
phenolate mofetil (23.8%, P= .002) and hydroxychloroquine
(9.5%, P= .02), compared with other patients. Conversely, no
significant difference was observed between groups in terms of
treatment with prednisone.
At the end of the study, side-by-side comparison showed
that survival was similar across the 3 groups. Long-term
functional follow-up (1 year) showed that, according to the
etiological groups, functional progression was similar across the
groups.
Table 3









Rheumatoid factor 0 (0%) 7 (36.8%)‡ 2 (2.6%)x <.001
Antinuclear antibody (≥1:320) 10 (41.7%) 8 (40%) 17 (19.8%)† .04
Anti-CCP antibody 2 (8.7%) 0 (0%) 3 (3.5%) .35
Anti-dsDNA antibody 3 (12.5%) 4 (25%) 6 (7.1%) .10
Anti-Crithidia Lucillae antibody 1 (4.3%) 1 (7.7%) 1 (1.3%) .48
Anti-Sm antibody 0 (0%) 0 (0%) 0 (0%)
Anti-SSA (Ro) antibody 1 (4.2%) 4 (25%) 1 (1.3%)x <.001
Anti-SSB (La) antibody 1 (4.2%) 1 (7.7%) 1 (1.3%) .48
Anti-RNP antibody 0 (0%) 1 (7.7%) 1 (1.3%) .28
Anti-centromere antibody 1 (4.3%) 0 (0%) 0 (0%) .12
Anti-Jo1 antibody 1 (4.2%) 2 (12.5%) 0 (0%)x .01
Anti-Scl70 antibody 1 (4.2%) 3 (18.8%) 0 (0%)x <.001
Anti-PL7 antibody 3 (12.5%) 0 (0%) 1 (1.3%)† .02
Anti-PL12 antibody 1 (4.2%) 4 (25%) 0 (0%)x <.001
Anti-EJ antibody 1 (4.2%) 0 (0%) 0 (0%) .13
Anti-OJ antibody 0 (0%) 0 (0%) 1 (1.3%) .78
Anti-PM-Scl antibody 4 (17.4%) 1 (7.7%) 3 (3.5%)† .06
Anti-Mi2 antibody 1 (4.2%) 1 (7.7%) 1 (1.3%) .48
Anti-Ku antibody 2 (8.7%) 1 (7.7%) 6 (7.1%) .97
Anti-SRP antibody 1 (4.2%) 0 (0%) 1 (1.3%) .53
Anti-Ro52 antibody 1 (4.2%) 5 (31.2%)‡ 0 (0%)x <.001
ANCA 0 (0%) 0 (0%) 2 (12.5%)x .02
ANCA= antineutrophil cytoplasmic antibodies, CCP= cyclic citrullinated peptide, CTD-ILD=
connective tissue disease-associated interstitial lung disease, dsDNA=double-stranded DNA,
ILD= interstitial lung disease, IPAF= interstitial pneumonia with autoinmune features, RNP=
ribonucleoprotein, SRP= signal recognition particle.
∗
IPAF as defined by the European Respiratory Society/American Thoracic Society research
statement’s criteria.[21]
† P< .05 for comparison between IPAF and other ILD forms groups.
‡ P< .05 for comparison between IPAF and CTD-ILD groups.
x P< .05 for comparison between CTD-ILD and other ILD forms groups.
Table 4









NSIP 15 (63.5%) 12 (57.1%) 13 (13.8%)†,‡ <.001
OP 2 (8.3%) 2 (9.5%) 5 (5.3%) .72
LIP 0 (0%) 1 (4.8%) 0 (0%)‡ .06
UIP 1 (4.2%) 2 (9.5%) 16 (17%) .22
Posible UIP 0 (0%) 1 (4.8%) 13 (13.8%) .09
Other pattern 6 (25%) 3 (14.3%) 47 (50%)†,‡ .003
Histopathology classification
NSIP 0 (0%) 0 (0%) 3 (3.2%) .68
OP 0 (0%) 3 (14.3%) 5 (5.3%) .12
LIP 0 (0%) 1 (4.8%) 0 (0%) .34
UIP 2 (8.3%) 3 (14.3%) 5 (5.3%)† .02
Posible/probable UIP 0 (0%) 1 (4.8%) 10 (10.6%) .55
Other pattern 2 (8.3%) 2 (9.5%) 32 (34%)‡ .11
Multicompartment involvement
PH 5 (3.6%) 3 (2.2%) 12 (8.6%) .60
Pleural/pericardial effusion
or thickening
0 (0%) 0 (0%) 3 (2.2%) .48
CTD-ILD= connective tissue disease-associated interstitial lung disease, HRCT=high resolution
computed tomography, ILD= interstitial lung disease, IPAF= interstitial pneumonia with autoimmune
features, LIP= lymphoid interstitial pneumonia, NSIP=nonspecific interstitial pneumonia, OP=
organizing pneumonia, PH=pulmonary hypertension, UIP=usual interstitial pneumonia.
∗
IPAF as defined by the European Respiratory Society/American Thoracic Society research
statement’s criteria.[21]
† P< .05 for comparison between IPAF and other ILD forms groups.
‡ P< .05 for comparison between CTD-ILD and other ILD forms groups.
Hernandez-Gonzalez et al. Medicine (2020) 99:4 Medicine4. Discussion
To the best of our knowledge, this is the first prospective study to
assess the impact of a systematic diagnostic strategy to detectFigure 2. Multivariate analysis for factors associated with the diagnosis of conne
autoimmune features. CI=confidence interval, HCRT=high resolution computed
6
CTD in patients presenting ILD. We have demonstrated that this
systematic approach is useful, and also supports the notion that
consideration for a classifiable CTD should be warranted in every
patient with ILD. Indeed, 15.1% of patients were confirmed to
have a new CTD-ILD diagnosis, which is similar to the
percentage reported by Mittoo and colleagues.[13]
From the beginning of the study, as there was a lack of
consensus concerning nomenclature and classification, wective tissue disease related interstitial pneumonia or interstitial pneumonia with
tomography, NS=not significant, OR=odds ratio.
Figure 3. The assessment of factors associated with connective tissue disease related interstitial pneumonia or interstitial pneumonia with autoimmune features
using decision tree analysis. CTD=connective tissue disease, CTD-ILD=connective tissue disease-associated interstitial lung disease, ILD= interstitial lung
disease, IPAF= interstitial pneumonia with autoimmune features.
Hernandez-Gonzalez et al. Medicine (2020) 99:4 www.md-journal.comprospectively collected both, specific and nonspecific features.
However, we agreed with other researchers that the presence of
some non-specific serologic or clinical findings alone might be
insufficient for a defined CTD diagnosis.[1,3,12,31] Thus, in orderTable 5








Treatments at some point during follow-up
Corticosteroids 8 (33.3%) 10 (47.6%) 25 (26.6%) .16
Mycophenolate mofetil 0 (0%) 5 (23.8%) 4 (4.3%)† .002
Azathioprine 0 (0%) 1 (4.8%) 3 (3.2%) .60
Cyclophosphamide 1 (4.2%) 1 (4.8%) 0 (0%) .12
Hydroxychloroquine 0 (0%) 2 (9.5%) 0 (0%)† .02
One-year survival 20 (83.3%) 18 (85.7%) 78 (83%) .95
Long-term evolution of PFTs (1-yr follow-up)
Functional progression‡ 5 (25%) 5 (27.8%) 15 (19.2%) .64
CTD-ILD= connective tissue disease-associated interstitial lung disease, ILD= interstitial lung
disease, IPAF= interstitial pneumonia with autoimmune features, PFTs=pulmonary function tests.
∗
IPAF as defined by the European Respiratory Society/American Thoracic Society research
statement’s criteria.[21]
† P< .05 for comparison between CTD-ILD and other ILD forms group.
‡ Defined as a decrease of Forced vital capacity≥10% or diffusion capacity for carbon monoxide≥15%.
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to properly classify patients with IPAF, we used only the specific
criteria proposed in the ERS/ATS statement. We found that we
were able to detect a lower percentage of patients with
autoimmune features compared with other series using broader
criteria for undifferentiated CTD (UCTD).[18,31,32]
In our study, the presence of specific clinical and serologic
features in patients with ILD was considered significant
independent prognostic factors of CTD-ILD or IPAF on
multivariate analysis. More than 60% of UCTD patients in
Kinder’s study presented Raynaud phenomenon and arthralgia
criteria.[18] Kondoh et al showed 13% of Raynaud phenomenon
and 21% of arthralgia in UCTD patients.[31] Oldham and
colleagues described that the most common clinical findings were
Raynaud’s phenomenon (27.8%) and inflammatory arthritis
(17.4%) in their IPAF cohort.[33] Our results showed that the
proportion of Raynaud phenomenon in IPAF is even lower
(4.2%), and inflammatory arthropathy was present in 37.5% of
patients with IPAF. In our cohort, we also found significant
differences between some other specific and nonspecific features.
Overall, we deduce that variability in population among studies
may be a possible explanation for these differences. However, as
no gold standard exists against which to validate IPAF criteria,
we questioned whether using classification criteria for IPAF in
patients with ILD leads to the exclusion of some patients who
Hernandez-Gonzalez et al. Medicine (2020) 99:4 Medicinemight be diagnosed as having a CTD.[34] Therefore, we suggest
that non-specific features should not be excluded from the routine
clinical practice.
On the other hand, we also showed that the detection of some
ASSD antibodies, such as anti-PL7 or anti-PL12, in IPAF patients
during the follow up may lead to patients’ misclassification.
Although these antibodies are markers of ASSD, complete forms
of the entity are characterized by the occurrence of myositis, ILD
and arthritis, and there is a lack of well-established clinicosero-
logical classification criteria.[29,35,36] In our study, at the end of
the 1-year follow-up these patients were still classified as IPAF,
but it has been suggested that this is generally a transient
condition that may progress into a well-defined ASSD during a
longer period. These considerations, together with the possible
presence of minor features of ASSD, suggest that ASSD
antibodies and an exhaustive multidisciplinary evaluation and
follow-up should be carefully considered in all patients presenting
with ILD. In accordance to this, our results support the need of
newly established classification criteria for ASSD based on
differential weights for various clinical, pathological, and
serological features, as well as validated criteria for IPAF.
According to the criteria proposed by Fischer et al, we have
also found that a patient without morphologic autoimmune
features would need to have at least 1 feature from the other 2
domains (clinical or serologic features) to be considered more
likely to have an IPAF or CTD-ILD.[21] Our study showed that
NSIP pattern in HRCT scan was the most frequently found in
CTD-ILD or IPAF, as suggested by other authors.[37] However,
there were a considerable percentage of patients with other
patterns, including UIP.[38,39] Consequently, these results rein-
force the importance of screening IPAF or CTD-ILD in all
patients with suspected IIPs, especially when IPF is suspected.
Previous studies suggested that UCTD or IPAF was not
associated with improved survival.[3,40,41] However, a further
study with a larger cohort demonstrated that the prognosis of
UCTD in patients with UIP was decreased.[42] Similarly, Churg
et al and Kim et al noted that the presence of UIP pattern is
associated with worse survival when concomitant honeycombing
is present in IPAF patients.[43,44] The present study showed that a
diagnosis of IPAF had no influence on 1-year survival compared
to other ILD patients. Besides, there were no significant
differences in functional progression between the groups, perhaps
due to the predominance of NSIP pattern and the effectiveness of
immunosuppressive therapy in this group. Nonetheless, mainly
regarding the relatively short period of follow-up, we consider
that multicenter registers over a longer period of time are needed
to study a possible evolution that may complete the clinical
picture and demonstrate differences between IPAF and other ILD
patients.
Our study has several strengths. In the first place, all the
variables included in the analysis were collected prospectively.
Second, all patients were assessed by a multidisciplinary panel of
ILD experts and autoimmune specialists. Nevertheless, our study
contains some limitations. Firstly, the fairly short duration of
follow-up might increase the risk of missing patients with late
development of CTD. Second, this study included a small
population of a single center. Further studies are therefore needed
to ascertain whether this result applies equally to other ethnic
cohorts. Third, lung biopsy is rarely performed in the context of
CTD, which might make it difficult to confirm suggestive patterns
detected by theHRCT scan, especially the diagnosis of NSIP. This
issuemay detract from the predictive value of surgical lung biopsy8
patterns in the proposed algorithm, so we believe that its value
needs to be further explored in future studies.
In conclusion, this study in a prospective cohort shows that
the present systematic strategy to identify patients with a clear
autoimmune flavor might well be useful when assessing ILD
patients, and contributes to the evidence-based data.Moreover,
this diagnostic approach seems to be both sensitive and specific
for CTD-ILD or IPAF diagnosis. Because there are several
implications of an early diagnosis of CTD-ILD, this study
reminds us that a comprehensive and multidisciplinary
approach, including specialists in autoimmune diseases, is
essential to explore all potential aetiologies in an ILD of recent
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